Arbor Biotechnologies Stock

arbor.bioHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $231.6MM

Arbor Biotechnologies uses AI and machine learning to develop gene editing therapeutics that aim to treat genomic diseases. Their current pipeline focuses on liver and Central Nervous System (CNS) diseases. Arbor Biotechnologies was founded in 2016 by David Scott Ph.D., Winston Yan Ph.D., David Walt Ph.D., and Feng Zhang Ph.D. and is headquartered in Cambridge, MA.

Register for Details

For more details on financing and valuation for Arbor Biotechnologies, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Arbor Biotechnologies.

Register Today


Management Team

David Cheng
Chief Technology Officer
John Murphy
Chief Scientific Officer
David Scott Ph.D
Co-Founder & Head of Innovation
Winston Yan Ph.D
Co-Founder & Head of Translational Strategy
Devyn Smith Ph.D
Chief Executive Officer & Board Member
Pam Stetkiewicz Ph.D
Chief Operating Officer

Board Members

Chen-Ming Yu MD
TCG Crossover Management
Keith Crandell
ARCH Venture Partners

Other companies like Arbor Biotechnologies in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Vertex, Arbor Biotechnologies extend agreement on precision gene editing technology
Vertex Pharmaceuticals (NASDAQ:VRTX) and Arbor Biotechnologies have extended a collaboration agreement that will provide the former with rights to the latter's novel precision editing technology for up to three diseases.
After Prime Medicine, What's the Next Gene Editing IPO?
Investors enjoyed a record number of biotech IPOs in 2020 and 2021 as companies raced to grab bags of money from public markets flooded with liquidity. The pipeline has dried up considerably in 2022, primarily due to tightening financial conditions. It's not quite as fun, but it's a sign of healthy markets.
Gene editing advances continue a pace, but progress is still early: panel
With the first-ever approval of a CRISPR gene editing therapy expected in 2023, companies at last week’s Cell & Gene Meeting on the Mesa (MOTM) say they are looking forward to other near- and longer-term breakthrough technologies on the horizon.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.